Pruritus and fatigue associated with liver disease: is there a role for ondansetron?

Bibliography

• Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999;38:1083-152
   PubMed Web of Science ®Google Scholar
• Roila F, Ballatori E, Tonato M, Del Favero A. 5-HT3 receptor antagonists: differences and similarities. Eur J Cancer 1997;33:1364-70
   PubMed Web of Science ®Google Scholar
• Wilde MI, Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs 1996;52:773-94
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Lummis SC. The 5-HT3 receptor as a therapeutic target. Exp Opin Ther Targets 2007;11:527-40
   PubMed Web of Science ®Google Scholar
• Gershon MD, Tack J. The serotonin signalling system: from basic understanding to drug development for functional gastrointestinal disorders. Gastroenterology 2007;132:397-414
   PubMed Web of Science ®Google Scholar
• Bloom FE, Morales M. The central 5-HT3 receptor in CNS disorders. Neurochem Res 1998;23:653-9
   PubMedGoogle Scholar
• Walton SM. Advances in use of 5-HT3 receptor antagonists. Exp Opin Pharmacother 2000;1:207-23
   PubMedGoogle Scholar
• Faeber L, Drechsler S, Ladenburger S, et al. The neuronal 5-HT3 receptor network after 20 years research – evolving concepts in management of pain and inflammation. Eur J Pharmacol 2007;560:1-8
   PubMedGoogle Scholar
• van Hooft JA, Vijverberg HP. 5-HT(3) receptors and neurotransmitter release in the CNS: a nerve ending story? Trends Neurosci 2000;23:605-10
   PubMedGoogle Scholar
• Reeves DC, Lummis SC. The molecular basis of the structure and function of the 5-HT3 receptor: a model ligand-gated ion channel. Mol Membr Biol 2002;19:11-26
   PubMed Web of Science ®Google Scholar
• Jones EA. Potential mechanisms of enhanced GABA-mediated inhibitory neurotransmission in liver failure. Neurochem Int 2003;43:509-16
   PubMed Web of Science ®Google Scholar
• Jones EA, Bergasa NV. The pruritus of cholestasis. From bile acids to opiate agonists. Hepatology 1990;11:884-7
   PubMed Web of Science ®Google Scholar
• Meta M, Mancuso A, Burroughs AK. Pruritus in cholestatic and other liver diseases. Aliment Pharmacol Ther 2003;17:857-70
   PubMedGoogle Scholar
• Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology 1999;29:1003-6
   PubMed Web of Science ®Google Scholar
• Bergasa NV, Alling DW, Talbot TL, et al. Effects of naloxone infusions in patients with the pruritus of cholestasis: a double-blind randomized controlled trial. Ann Intern Med 1995;123:161-7
   PubMed Web of Science ®Google Scholar
• Bergasa NV, Alling DW, Talbot TL, et al. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Derm 1999;41:431-4
   PubMed Web of Science ®Google Scholar
• Richardson BP. Serotonin and nociception. Ann NY Acad Sci 1990;600:511-20
   PubMed Web of Science ®Google Scholar
• Kiefel JM, Cooper ML, Bodnar RJ. Serotonin receptor subtype antagonists in the medial ventral medulla inhibit mesencephalic opiate analgesia. Brain Res 1992;597:331-8
   PubMedGoogle Scholar
• De Witte JL, Schoenmaekers B, Sessler DI. The analgesic efficacy of tramadol is impaired by concurrent administration of ondansetron. Anesth Analg 2001;92:1319-21
   PubMed Web of Science ®Google Scholar
• Arcioni R, della Rocca M, Romano S, et al. Ondansetron inhibits the analgesic effects of tramadol: a possible 5-HT3 spinal receptor involvement in acute pain in humans. Anesth Analg 2002;94:1553-7
   PubMed Web of Science ®Google Scholar
• Pinelli A, Trivulzio S, Tomasoni L. Effects of ondansetron administration on opioid withdrawal syndrome observed in rats. Eur J Pharmacol 1997;340:111-9
   PubMed Web of Science ®Google Scholar
• Kyriakides K, Hussain SK, Hobbs GJ. Management of opioid-induced pruritus: a role for 5-HT3 antagonists? Br J Anaesth 1999;82:439-41
   PubMed Web of Science ®Google Scholar
• Iatrou CA, Dragoumanis CK, Vogiatzaki TD, et al. Prophylactic intravenous ondansetron and dolasetron in intrathecal morphine-induced pruritus: a randomized, double-blinded, placebo-controlled study. Anesth Analg 2005;101:1516-20
   PubMedGoogle Scholar
• Pirat A, Tuncay SF, Torgay A, et al. Ondansetron, orally disintegrating tablets versus intravenous injection for prevention of intrathecal morphine-induced nausea, vomiting, and pruritus in young males. Anesth Analg 2005;101:1330-6
   PubMed Web of Science ®Google Scholar
• Schworer H, Ramadori G. Treatment of pruritus: a new indication for serotonin type 3 receptor antagonists. Clin Invest 1993;71:659-62
   PubMedGoogle Scholar
• Schworer H, Ramadori G. Improvement in cholstatic pruritus by ondansetron. Lancet 1993;341:1277
   PubMed Web of Science ®Google Scholar
• Raderer M, Muller C, Scheithauer W. Ondansetron for pruritus due to cholestasis. N Engl J Med 1994;330:1540
   PubMed Web of Science ®Google Scholar
• Schworer H, Ramadori G. Cholestatic pruritus – pathophysiology and therapy with special reference to treatment with 5-hydtroxytryptamine subtype 3 receptor antagonists. Z Gastroenterol 1995;33:265-74
   PubMedGoogle Scholar
• Di Martino M, Galanti B, Nardiello S. Treatment of cholestatic itching in primary biliary cirrhosis with ondansetron. Ital J Gastroenterol 1996;27:455
   Google Scholar
• Trioche P, Samuel D, Odievre M, Labrune P. Ondansetron for pruritus in child with chronic cholestasis. Eur J Pediatr 1996;155:990
   PubMedGoogle Scholar
• Quigley C. 5HT3 receptor antagonists and pruritus due to cholestasis. Palliat Med 1996;10:54
   PubMedGoogle Scholar
• Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995;61:33-7
   PubMed Web of Science ®Google Scholar
• Muller C, Pongratz S, Pidlich J, et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998;10:865-70
   PubMed Web of Science ®Google Scholar
• McCormack HM, de L'Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med 1988;18:1007-19
   PubMed Web of Science ®Google Scholar
• Jones EA. Trials of opiate antagonists for the pruritus of cholestasis: primary efficacy endpoints and opioid withdrawal-like reactions. J Hepatol 2002;37:864-5
   Google Scholar
• Talbot TL, Schmitt JM, Bergasa NV, et al. Application of piezofilm technology for the quantitative assessment of pruritus. Biomed Instrum Technol 1991;25:400-3
   PubMedGoogle Scholar
• Molenaar HA, Oosting J, Jones EA. Improved device for measuring scratching activity in patients with pruritus. Med Biol Eng Comput 1998;36:220-4
   PubMedGoogle Scholar
• O'Donohue JW, Pereira SP, Ashdown AC, et al. A controlled trial of ondansetron in the pruritus of cholestasis. Aliment Pharmacol Ther 2005;21:1041-5
   PubMed Web of Science ®Google Scholar
• Jones EA, Molenaar HA, Oosting J. Ondansetron and pruritus in chronic liver disease: a controlled study. Hepatogastroenterology 2007;54:1196-9
   PubMedGoogle Scholar
• Goldblatt J, Taylor PJ, Lipman T, et al. The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology 2002;122:1235-41
   PubMed Web of Science ®Google Scholar
• Newton JL, Gibson GJ, Tomlinson M, et al. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology 2006;44:91-8
   PubMed Web of Science ®Google Scholar
• Wessely S, Pariante C. Fatigue, depression and chronic hepatitis C. Psychol Med 2002;32:1-10
   PubMed Web of Science ®Google Scholar
• Poynard T, Cacoub P, Ratziu V, et al. Fatigue in patients with chronic hepatitis C. Viral Hepat 2002;9:295-303
   PubMed Web of Science ®Google Scholar
• Wilson WM, Maughan RJ. Evidence for a possible role of 5-hydroxytryptamine in the genesis of fatigue in man: administration of paroxetine, a 5HT re-uptake inhibitor, reduces the capacity to perform prolonged exercise. Exp Physiol 1992;77:921-4
   PubMed Web of Science ®Google Scholar
• Bailey SP, Davis JM, Ahlborn EN. Neuroendocrine and substrate responses to altered brain 5-HT activity during prolonged exercise to fatigue. J Appl Physiol 1993;74:3006-12
   PubMed Web of Science ®Google Scholar
• Jones EA. Fatigue associated with chronic liver disease: a riddle wrapped in a mystery inside an enigma. Hepatology 1995;22:1606-8
   PubMedGoogle Scholar
• Jones EA, Yurdaydin C. Is fatigue associated with cholestasis mediated by altered central neurotransmission? Hepatology 1997;25:492-4
   PubMed Web of Science ®Google Scholar
• Jones EA. Altered central serotoninergic neurotransmission: a potential mechanism for profound fatigue complicating chronic hepatitis C. Med Hypoth 2001;57:133-4
   PubMedGoogle Scholar
• Jones EA. Relief from profound fatigue associated with chronic liver disease by long-term ondansetron therapy. Lancet 1999;354:397
   PubMedGoogle Scholar
• Theal JJ, Toosi MN, Girlan L, et al. A randomized controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue. Hepatology 2005;41:1305-12
   PubMed Web of Science ®Google Scholar
• Piche T, Vanbiervliet G, Cherikh F, et al. Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomized, double-blind, placebo-controlled study. Gut 2005;54:1169-73
   PubMed Web of Science ®Google Scholar
• Revicki DA. Methodological issues and the measurement of fatigue in primary biliary cirrhosis. Hepatology 2005;42:24-6
   PubMedGoogle Scholar
• Motu DD, Pimenta CA. Self-report instruments for fatigue assessment: a systematic review. Res Theory Nurs Pract 2006;20:49-78
   PubMedGoogle Scholar
• Jones EA. A potential novel treatment for fatigue complicating chronic liver disease: how should its efficacy be evaluated? Aliment Pharmacol Ther 2006;23:1113-6
   PubMed Web of Science ®Google Scholar
• Bruce RA. Exercise testing in patients with coronary disease. Principles and normal standards for evaluation. Ann Clin Res 1971;3:323-32
   PubMedGoogle Scholar
• Goldblatt J, James OF, Jones DE. Grip strength and subjective fatigue in patients with primary biliary cirrhosis. J Am Med Assoc 2001;285:2196-7
   PubMed Web of Science ®Google Scholar
• Jalan R, Gibson H, Lombard MG. Patients with PBC have central but not peripheral fatigue. Hepatology 1996;24(Suppl 1):A167A
   Google Scholar
• Le Fanu J. Looking to the future. In: The Rise and Fall of Modern Medicine. London: Little, Brown and Company; 1999. p. 406-7
   Google Scholar